Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
17-18
|
| pubmed:dateCreated |
1997-5-9
|
| pubmed:abstractText |
The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36-68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer < or = 1:64 (equivalent to < or = 1:16 on the Western scale; in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0-50% at > or = 1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer > or = 1:128) among those with a prevaccination titer < 1:16 remained at 48-68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P < or = 0.002), but not for age (P > or = 0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P = 0.030), while it was also suggestive for A/Beijing (P = 0.054): as age increased, those with no preexisting antibody (< 1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer > or = 1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever < or = 37 degrees C and > or = 37.5 degrees C was calculated to be 16% (95% confidence interval: -66% to 57%) and 37% (-55% to 74%), respectively.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0264-410X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1597-602
|
| pubmed:dateRevised |
2005-11-22
|
| pubmed:meshHeading |
pubmed-meshheading:9032887-Adult,
pubmed-meshheading:9032887-Aged,
pubmed-meshheading:9032887-Aging,
pubmed-meshheading:9032887-Antibodies, Viral,
pubmed-meshheading:9032887-Disease Outbreaks,
pubmed-meshheading:9032887-Female,
pubmed-meshheading:9032887-Hemagglutination Inhibition Tests,
pubmed-meshheading:9032887-Humans,
pubmed-meshheading:9032887-Influenza, Human,
pubmed-meshheading:9032887-Influenza Vaccines,
pubmed-meshheading:9032887-Japan,
pubmed-meshheading:9032887-Male,
pubmed-meshheading:9032887-Middle Aged,
pubmed-meshheading:9032887-Reference Values,
pubmed-meshheading:9032887-Titrimetry,
pubmed-meshheading:9032887-Vaccines, Inactivated
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age.
|
| pubmed:affiliation |
Department of Public Health, Faculty of Medicine 60, Kyushu University, Fukuoka, Japan.
|
| pubmed:publicationType |
Journal Article
|